Heinzmann, Dominik

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

Ismael, G., Hegg, R., Muehlbauer, S., Heinzmann, D., Lum, B., Kim, S.-B., Pienkowski, T., Lichinitser, M., Semiglazov, V., Melichar, B., et al. (2012) · The Lancet Oncology

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 351

Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical Trial

Jackisch, C., Stroyakovskiy, D., Pivot, X., Ahn, J. S., Melichar, B., Chen, S.-C., Meyenberg, C., Al-Sakaff, N., Heinzmann, D., & Hegg, R. (2019) · JAMA Oncology

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 84

Immunogenicity of Trastuzumab Intravenous and Subcutaneous Formulations in the Phase III Hannah Study

Hegg, R., Pienkowski, T., Chen, S., Staroslawska, E., Falcon, S., Kovalenko, N., Al-Sakaff, N., Heinzmann, D., Kolaitis, G., & Ismael, G. (2012) · Annals of Oncology

HER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies Research

Cited by 9

Abstract PD3-11: Efficacy and safety of subcutaneous or intravenous trastuzumab in patients with HER2-positive early breast cancer after 5 years' treatment-free follow-up: Final analysis from the phase III, open-label, randomized HannaH study

Jackisch, C., Stroyakovskiy, D., Pivot, X., Ahn, J.-S., Melichar, B., Chen, S.-C., Meyenberg, C., Al-Sakaff, N., Heinzmann, D., & Hegg, R. (2018) · Cancer Research

HER2/EGFR in Cancer ResearchBreast Cancer Treatment Studies

Cited by 1